Changes in Regional Cerebral Perfusion After Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study

Overview

Journal Dement Neurocogn Disord

Date 2019 Mar 26

PMID 30906380

Citations 4

Authors

Jooyeon J Im

Hyeonseok S Jeong

Jong-Sik Park

YoungSoon Yang

Seung-Hee Na

Jin Kyoung Oh

Yong-An Chung

In-Uk Song

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Nicergoline is an ergoline derivative that is used to treat cognitive deficits in cerebrovascular disease and various forms of dementia. Although therapeutic effects of nicergoline have been established, little is known about its effects on cerebral perfusion in Alzheimer's disease (AD). The aim of this study was to examine the role of nicergoline in regional cerebral blood flow (rCBF) of AD patients using technetium-99m hexa-methyl-propylene-amine-oxime single photon emission computed tomography (SPECT).

Methods: Sixteen patients with early AD underwent a comprehensive clinical assessment including cognitive testing and SPECT scans before and after nicergoline treatment. Nicergoline (30 mg twice daily) was administered for an average duration of 1.5 years. Clinical and cognitive functioning was assessed using the Mini-Mental State Examination, Clinical Dementia Rating (CDR), CDR-Sum of Boxes, Global Deterioration Scale, Barthel Activities of Daily Living Index, Instrumental Activities of Daily Living, and Geriatric Depression Scale.

Results: Nicergoline treatment induced changes in the severity of dementia, cognitive function, activities of daily living, and depressive symptoms, which were not statistically significant. During the follow-up, the patients showed significant increases in their relative rCBF in the superior frontal gyrus, precentral gyrus, and postcentral gyrus.

Conclusions: Nicergoline treatment improves perfusion of the frontal and parietal regions in early AD patients. It is possible that the increased perfusion in the superior frontal gyrus may be related to the mechanisms that delay or prevent progressive deterioration of cognitive functions in AD.

Citing Articles

Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease.

Dong H, Guo L, Yang H, Zhu W, Liu F, Xie Y Front Aging Neurosci. 2023; 15:1129051.

PMID: 37091519 PMC: 10117777. DOI: 10.3389/fnagi.2023.1129051.

Involvement of cerebrovascular abnormalities in the pathogenesis and progression of Alzheimer's disease: an adrenergic approach.

Li S, Wang C, Wang Z, Tan J Aging (Albany NY). 2021; 13(17):21791-21806.

PMID: 34479211 PMC: 8457611. DOI: 10.18632/aging.203482.

Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection.

Abourehab M, Khames A, Genedy S, Mostafa S, Khaleel M, Omar M Pharmaceutics. 2021; 13(4).

PMID: 33921796 PMC: 8072759. DOI: 10.3390/pharmaceutics13040581.

Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Sanders O, Rajagopal L J Alzheimers Dis Rep. 2020; 4(1):185-215.

PMID: 32715279 PMC: 7369141. DOI: 10.3233/ADR-200191.

References

Sortino M, Battaglia A, Pamparana F, Carfagna N, Post C, Canonico P . Neuroprotective effects of nicergoline in immortalized neurons. Eur J Pharmacol. 1999; 368(2-3):285-90. DOI: 10.1016/s0014-2999(99)00041-2. View

Cedazo-Minguez A, Bonecchi L, Winblad B, Post C, Wong E, Cowburn R . Nicergoline stimulates protein kinase C mediated alpha-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells. Neurochem Int. 1999; 35(4):307-15. DOI: 10.1016/s0197-0186(99)00074-1. View

Pickut B, Dierckx R, Dobbeleir A, Audenaert K, Van Laere K, Vervaet A . Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res. 1999; 90(2):103-12. DOI: 10.1016/s0925-4927(99)00004-9. View

Skoog I, Kalaria R, Breteler M . Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13 Suppl 3:S106-14. DOI: 10.1097/00002093-199912003-00016. View

Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T . Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000; 41(7):1155-62. View

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View

Scahill R, Schott J, Stevens J, Rossor M, Fox N . Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002; 99(7):4703-7. PMC: 123711. DOI: 10.1073/pnas.052587399. View

Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K . Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002; 43(8):983-90. View

Soonawala D, Amin T, Ebmeier K, Douglas Steele J, Dougall N, Best J . Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage. 2002; 17(3):1193-202. DOI: 10.1006/nimg.2002.1259. View

10.

Miccheli A, Puccetti C, Capuani G, Di Cocco M, Giardino L, Calza L . [1-13C]Glucose entry in neuronal and astrocytic intermediary metabolism of aged rats. A study of the effects of nicergoline treatment by 13C NMR spectroscopy. Brain Res. 2003; 966(1):116-25. DOI: 10.1016/s0006-8993(02)04217-8. View

11.

Resnick S, Pham D, Kraut M, Zonderman A, Davatzikos C . Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci. 2003; 23(8):3295-301. PMC: 6742337. View

12.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S . Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003; 30(8):1104-13. DOI: 10.1007/s00259-003-1194-1. View

13.

Scarpini E, Scheltens P, Feldman H . Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003; 2(9):539-47. DOI: 10.1016/s1474-4422(03)00502-7. View

14.

Encinas M, De Juan R, Marcos A, Gil P, Barabash A, Fernandez C . Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2003; 30(11):1473-80. DOI: 10.1007/s00259-003-1277-z. View

15.

Fox N, Schott J . Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet. 2004; 363(9406):392-4. DOI: 10.1016/S0140-6736(04)15441-X. View

16.

Ogawa N, Asanuma M, Hirata H, Kondo Y, Kawada Y, Mori A . Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr. 1993; 16(2):103-10. DOI: 10.1016/0167-4943(93)90001-x. View

17.

Gorelick P . Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004; 35(11 Suppl 1):2620-2. DOI: 10.1161/01.STR.0000143318.70292.47. View

18.

Coffey C, WILKINSON W, Parashos I, Soady S, Sullivan R, Patterson L . Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology. 1992; 42(3 Pt 1):527-36. DOI: 10.1212/wnl.42.3.527. View

19.

Benoit M, Robert P, Staccini P, Brocker P, Guerin O, Lechowski L . One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J Nutr Health Aging. 2005; 9(2):95-9. View

20.

Caraci F, Chisari M, Frasca G, Canonico P, Battaglia A, Calafiore M . Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. Brain Res. 2005; 1047(1):30-7. DOI: 10.1016/j.brainres.2005.04.004. View